InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Explore the complete record of transactions filed by Dier Mardi, Chief Financial Officer. Officer active across 2 companies, notably Adamas Pharmaceuticals Inc. Cumulatively, 5 filings have been published. Total volume traded: €531k. The latest transaction was filed on 1 March 2022 — Cession. Regulator: SEC (Form 4). All data is free.
Declarations5 total
€31,718534 shares@ €59.39770.0013% mcap6.0% of flow
Common Stock
SEC:0001209191-22-015833:0·
€249,5753,477 shares@ €71.77890.010% mcap100.0% of flow
Common Stock
SEC:0001209191-21-060504·
€249,5753,477 shares@ €71.77890.010% mcap47.0% of flow
Common Stock
SEC:0001209191-21-060504:0·
05,000 shares0
Common Stock
SEC:0001328143-21-000056·
05,000 shares0
Common Stock
SEC:0001328143-21-000056:0·
5 of 5 declarations
About Dier Mardi
Mardi Dier is the Chief Financial Officer and Executive Vice President at Adamas Pharmaceuticals Inc and Ultragenyx Pharmaceutical Inc. He is responsible for the financial management of these companies, including financial planning, risk management, and compliance. His financial expertise is essential to support the growth and strategy of both companies.
